Chapter review

Fitzgerald PMHNP board review. ch14. Older Adults. This is drive 5 of 7. When I say Pause. Answer. wait, then I will give the answer. New section. Master Comparison Matrix of MNCD Subtypes. Topic. Huntington’s Disease. Bottom Line Summary. * **Subcortical classification**: **Huntington's disease** is an **autosomal dominant** specifier of **major neurocognitive disorder** classified as a subcortical dementia, defined by motor dysfunction like **chorea** while **language** and **insight** remain preserved until late stages. * **Genetic screening timeline**: Genetic testing is indicated for early-onset neurocognitive presentations occurring before **age 65**, which accounts for fewer than **5 percent** of typical dementia cases. * **High psychiatric comorbidity**: Up to **50 percent** of individuals with **major neurocognitive disorder** suffer from co-occurring **depression**, and **98 percent** exhibit neuropsychiatric symptoms over their clinical course. * **First-line depression care**: **First-line** pharmacotherapy for co-occurring depressive symptoms in neurocognitive disorders is an **SSRI** such as **sertraline**. * **Safety alert on hyponatremia**: **SSRIs** carry a **safety alert** for **hyponatremia** in older adults, especially when combined with diuretics like **hydrochlorothiazide**, elevating the risk for **delirium** and **falls**. * **Safety alert on antipsychotic mortality**: **Antipsychotics** carry an FDA **boxed warning** for a **1.6 to 1.7 times** increased risk of mortality in older adults with NCD-related psychosis, primarily from **cardiovascular events** or **pneumonia**. * **Board trap on antipsychotic indications**: **Board trap**: Prescribing **antipsychotics** for wandering, mild irritability, or uncooperativeness is incorrect; they do not improve cognition or quality of life and are reserved only for severe agitation or immediate safety risks. High-Yield Concept Review: Huntington's Disease. Clinical Features and Subcortical Distinction. **Huntington's disease** is an inherited, **autosomal dominant** neurodegenerative disorder that serves as a diagnostic specifier for **major neurocognitive disorder**. It is classified as a subcortical dementia because the primary neuropathology targets subcortical structures like the basal ganglia. The hallmark physical presentation is **chorea**, characterized by involuntary, dance-like, irregular movements. A critical diagnostic distinction tested on board exams is that cortical functions such as **language** and **insight** remain relatively preserved until the late stages of **Huntington's disease**. **Board trap**: Do not confuse cortical dementias with subcortical dementias. Think **Alzheimer's disease** when early memory loss, aphasia, and executive dysfunction precede motor signs. Think **Huntington's disease** when prominent motor symptoms like **chorea** and early personality changes occur while language skills remain intact. Neuropsychiatric Management and Safety. Patients with **Huntington's disease** experience a high incidence of early psychiatric disturbances, including severe **depression**, irritability, impulse control deficits, and **psychosis** (delusions and hallucinations). **First-line**: **First-line** management for co-occurring mood symptoms is a selective serotonin reuptake inhibitor such as **sertraline**. Standardized depression screening tools like the **PHQ-9** remain valid and reliable in older adults over **age 65**. **Safety alert**: Monitor older patients started on an **SSRI** for **hyponatremia**. Combining **SSRIs** with antihypertensives like **lisinopril** or diuretics like **hydrochlorothiazide** increases sodium loss, which can precipitate acute **delirium** and severe **falls**. When severe behavioral agitation or psychotic symptoms jeopardize patient safety, low-dose **second-generation antipsychotics** such as **risperidone**, **quetiapine**, or **olanzapine** may be considered. **Safety alert**: All **antipsychotics** carry a black box warning when used in older adults with neurocognitive disorders due to a **1.6 to 1.7 times** higher mortality rate compared to placebo. Deaths are most often caused by **heart failure**, **sudden cardiac death**, or **pneumonia**. **Board trap**: Avoid prescribing **antipsychotics** for routine behavioral disturbances, wandering, or mild agitation. Antipsychotics do not improve wandering, functional status, or overall quality of life. Reserve them strictly for severe agitation or active safety hazards. Board Practice Questions. Question 1. Which of the following is the least likely characteristic of **Alzheimer's disease**? A) Slowly developing impairment of cognitive function B) Chronic condition without reversal C) Perceptual disturbances including hallucinations D) Progressive and irreversible Pause. Answer: C. Why It Is Correct. Perceptual disturbances such as early hallucinations are least characteristic of **Alzheimer's disease**. Early hallucinations, fluctuating cognition, and REM sleep behavior disorder are classic hallmarks of **Lewy body disease** or subcortical psychotic presentations rather than uncomplicated **Alzheimer's disease**. Why the Other Choices Are Wrong. * **A:** Incorrect because **Alzheimer's disease** typically presents with a slow, insidious onset of cognitive decline. * **B:** Incorrect because **Alzheimer's disease** is a chronic, non-reversible neurodegenerative disorder. * **D:** Incorrect because the clinical course of **Alzheimer's disease** is continuously progressive and irreversible. Question 2. Your patient with **major neurocognitive disorder** develops severe bradycardia, gait disturbances, rigidity, and tremor after taking a low dose **second-generation antipsychotic** for severe hallucinations. Which neurocognitive disorder type do you suspect? A) **Alzheimer's disease** B) **Vascular disease** C) **Frontotemporal disease** D) **Lewy body disease** Pause. Answer: D. Why It Is Correct. Patients with **Lewy body disease** possess extreme neuroleptic sensitivity. Administering even low doses of **atypical antipsychotics** can trigger severe parkinsonism, profound rigidity, marked gait impairment, or neuroleptic malignant syndrome. Why the Other Choices Are Wrong. * **A:** Incorrect because **Alzheimer's disease** does not display severe, immediate extrapyramidal sensitivity to low-dose antipsychotics. * **B:** Incorrect because **Vascular disease** presents with stepwise cognitive decline linked to cardiovascular risk factors or strokes. * **C:** Incorrect because **Frontotemporal disease** presents primarily with early behavioral disinhibition, apathy, or primary progressive aphasia rather than extreme neuroleptic sensitivity. Next. New section. Neuropsychiatric Symptoms (NPS) Management. Topic. Antipsychotic Treatment Limits. Antipsychotic Treatment Limits in Neuropsychiatric Symptoms Management. Bottom Line. * **98% of patients** with major neurocognitive disorders experience neuropsychiatric symptoms during their illness, driving severe caregiver burden and early nursing home placement. * **Antipsychotic indications** are strictly limited to severe, dangerous agitation or active physical safety threats, never for wandering, uncooperativeness, or routine insomnia. * **Boxed Warning mortality risk** demonstrates a **1.6 to 1.7 times increased mortality rate** in elderly patients with neurocognitive disorder related psychosis treated with antipsychotics compared to placebo across 17 controlled trials. * **Primary mortality causes** linked to antipsychotic use in older adults are cardiovascular events such as heart failure or sudden cardiac death, and respiratory infections such as aspiration pneumonia. * **Brexpiprazole** holds an FDA indication for agitation associated with dementia due to Alzheimer's disease at low doses, but it still carries the full FDA Boxed Warning for increased elderly mortality. * **Off-label SGA choices** like low-dose **risperidone**, **quetiapine**, or **olanzapine** carry elevated risks of cerebrovascular accidents and ischemic stroke. * **Lewy body disease sensitivity** causes extreme neuroleptic hypersensitivity, where even low-dose antipsychotics trigger severe parkinsonism, rigidity, or neuroleptic malignant syndrome. High-Yield Clinical Concepts and Limits. **Non-Pharmacological First-Line Strategy** * **First-line**: Non-pharmacological interventions are the mandatory first step for managing mild to moderate neuropsychiatric symptoms in older adults. * **Clinical actions**: Identify underlying physical or environmental triggers, re-establish structured daily routines, utilize redirection, offer calm reassurance, and implement home safety modifications. * **Safety alert**: Antipsychotics do not improve cognition, functional capacity, wandering, or overall quality of life, and they must never be prescribed as a substitute for behavioral or environmental management. **FDA Boxed Warning and Mortality Parameters** * **Safety alert**: All first-generation and second-generation antipsychotics carry an FDA Boxed Warning regarding increased mortality when administered to elderly patients with neurocognitive disorder related psychosis. * **Statistical risk**: Analysis of 17 placebo-controlled trials demonstrated a **1.6 to 1.7-fold increase in death rates** among drug-treated patients compared to placebo. * **Primary causes of death**: Sudden cardiac death, heart failure, and infectious complications including aspiration pneumonia. * **Cerebrovascular risk**: Antipsychotic therapy significantly elevates the incidence of transient ischemic attacks and ischemic stroke in older adults with major neurocognitive disorder. **Pharmacological Selection and Limits** * **FDA approved agent**: **Brexpiprazole** is low-dose approved for Alzheimer's dementia agitation, though it retains the black box warning. * **Off-label SGA agents**: Low-dose **quetiapine**, **risperidone**, or **olanzapine** may be used off-label when severe agitation poses an immediate safety hazard to the patient or caregivers. * **Board trap**: Prescribing an antipsychotic for minor irritability, verbal disruption, or sleep disturbance is a classic exam error. Use SSRIs like **sertraline** for mood or anxiety symptoms and cholinesterase inhibitors like **donepezil** for cognitive stabilization. **Dementia with Lewy Bodies Sensitivity** * **Safety alert**: Patients with **Lewy body disease** possess extreme neuroleptic sensitivity. * **Clinical hazard**: Administration of low-dose antipsychotics can precipitate severe extrapyramidal symptoms, marked bradycardia, muscle rigidity, neuroleptic malignant syndrome, or rapid cognitive decline. * **First-line choice if required**: If psychotic symptoms cause extreme distress or danger in Lewy body disease, ultra-low-dose **quetiapine** or **pimavanserin** is used with extreme caution. Board-Style Practice Questions. Question 1. Mrs. Little is a 78-year-old woman with recently diagnosed Alzheimer's disease who presents for an office visit with her 55-year-old daughter. Her daughter reports that Mrs. Little struggles with word finding, has difficulty following directions, and occasionally has angry verbal outbursts triggered by minor disruptions. Her daughter asks if a medication can be started to stop these angry verbal outbursts. Which of the following statements represents the most appropriate PMHNP clinical guidance regarding treatment limits? A) A second-generation antipsychotic should be initiated immediately to prevent future angry outbursts. B) Antipsychotics are contraindicated for non-emergent verbal outbursts and should only be used for severe agitation or immediate safety hazards. C) High-dose benzodiazepines should be added to manage behavioral disinhibition and agitation. D) Antipsychotics should be prescribed routinely to improve long-term cognitive functioning and prevent wandering. * **Quick Answer**: B. Antipsychotics are restricted to severe agitation or safety threats due to Boxed Warning mortality risks. * **Key Clue**: Angry verbal outbursts triggered by minor routine disruptions without immediate physical safety hazards. * **Best Answer**: B. Antipsychotics are contraindicated for non-emergent verbal outbursts and should only be used for severe agitation or immediate safety hazards. * **Why It Is Correct**: Antipsychotics carry an FDA Boxed Warning for increased mortality and stroke risk in elderly patients with neurocognitive disorders. They do not improve cognition or wandering and are not indicated for non-emergent verbal outbursts. Non-pharmacological environmental modifications and routine stabilization are first-line choices. * **Why the Other Choices Are Wrong**: * **A**: Initiating an SGA for non-emergent verbal outbursts exposes the patient to an unwarranted **1.6 to 1.7-fold increase in mortality risk** without cognitive benefit. * **C**: Benzodiazepines cause paradoxically increased disinhibition, worsening confusion, sedation, ataxia, and elevated fall risks in older adults. * **D**: Antipsychotics do not improve cognition, daily functioning, or wandering behaviors in major neurocognitive disorder. Question 2. A 71-year-old male with major neurocognitive disorder develops severe bradycardia, gait disturbance, profound rigidity, and tremors after receiving a single low dose of risperidone for visual hallucinations. Which underlying neurocognitive disorder subtype is most likely present? A) Alzheimer's disease B) Vascular neurocognitive disorder C) Frontotemporal neurocognitive disorder D) Lewy body disease * **Quick Answer**: D. Lewy body disease presents with extreme neuroleptic sensitivity to antipsychotics. * **Key Clue**: Severe extrapyramidal symptoms, rigidity, and bradycardia following a low dose SGA. * **Best Answer**: D. Lewy body disease. * **Why It Is Correct**: Lewy body disease is characterized by extreme neuroleptic sensitivity. Administering even low-dose second-generation antipsychotics can trigger severe parkinsonism, rigidity, profound bradycardia, or neuroleptic malignant syndrome. * **Why the Other Choices Are Wrong**: * **A**: Alzheimer's disease typically presents with insidious memory loss and does not exhibit acute severe extrapyramidal collapse from low-dose SGAs. * **B**: Vascular neurocognitive disorder causes stepwise cognitive decline from ischemic events without classic severe neuroleptic hypersensitivity. * **C**: Frontotemporal neurocognitive disorder presents with early behavioral disinhibition or primary progressive aphasia without severe extrapyramidal sensitivity. Next. Topic. Behavioral Management and Sleep. Bottom Line Summary. - **Neuropsychiatric symptoms (NPS)** occur in **98%** of patients with major neurocognitive disorders (NCDs), accelerating disease progression, driving caregiver burnout, and precipitating early nursing home placement [1, 2]. - **NPS categorizes into four clinical groups**: affective and motivational symptoms (depression, apathy, anxiety, irritability), psychotic symptoms (delusions, hallucinations), drive disturbances (feeding, sleep, sexuality), and disinhibited or executive behaviors (wandering, vocalizations) [3, 4]. - **First-line treatment** for behavioral disruptions and sleep alterations is always non-pharmacological, incorporating routine maintenance, environment modification, redirection, reassurance, and music therapy [5-7]. - **Pharmacotherapy for routine insomnia** in major NCD is **not indicated** [8, 9]; sedatives like **zolpidem** elevate fall and fracture risks source 10, while anticholinergics like **diphenhydramine** and benzodiazepines like **diazepam** precipitate acute delirium [11, 12]. - **Safety alert**: Antipsychotics carry an FDA **boxed warning** for older adults with NCD-related psychosis due to a **1.6 to 1.7 times increased risk of death**, primarily from cardiovascular collapse or pneumonia [13-15]. - **Antipsychotics do not improve** wandering, underlying cognition, physical functioning, or overall quality of life, and must be reserved strictly for severe agitation or immediate physical safety hazards [13, 16]. - **Brexpiprazole** is low-dose FDA-approved for Alzheimer's agitation, while low-dose **quetiapine**, **risperidone**, **olanzapine**, or **haloperidol** are used off-label with extreme caution [13, 16]. - **Board trap**: Patients with **Lewy body disease** possess extreme neuroleptic sensitivity; administering even low-dose antipsychotics can trigger life-threatening rigidity, severe parkinsonism, and neuroleptic malignant syndrome [17-20]. High-Yield Concept Map: NPS, Behavioral Management, and Sleep. Categorization of Neuropsychiatric Symptoms. - **Affective and motivational group**: Presents as co-occurring depression, profound apathy, generalized anxiety, and emotional irritability, best managed initially with **SSRIs** like **sertraline** rather than sedatives [3, 21, 22]. - **Psychotic symptoms group**: Encompasses persecutory delusions and visual or auditory hallucinations, requiring medical rule-outs before considering low-dose psychotropics [3, 23, 24]. - **Basic drive disturbances group**: Features severe disruptions in sleep-wake cycles, diurnal fluctuation (sundowning), hyperorality or reduced feeding, and altered sexual behaviors [3, 25]. - **Disinhibited behavior group**: Involves wandering, repetitive vocalizations, pacing, and socially inappropriate actions stemming from frontal executive dysfunction source 4. Non-Pharmacological Behavioral Interventions and Sleep Management. - **First-line approach**: Establish rigid daily routines, maintain consistent lighting to reduce evening sundowning, apply door alarms and stove shut-off timers for wandering, and utilize adult day care to alleviate caregiver burnout [6, 7, 26]. - **Cognitive and sensory interventions**: Implement reminiscence therapy, personalized music listening, non-confrontational communication, and immediate verbal reassurance during catastrophic outbursts [5, 7]. - **Safety alert**: Never prescribe sedatives, antihistamines, or long-acting benzodiazepines for routine nighttime sleep disturbances in dementia patients, as they impair gait and worsen cognitive confusion [8-12]. - **Board trap**: Assuming an angry outburst in a previously calm dementia patient requires immediate antipsychotics is a classic exam trap; always assess for underlying physical pain, urinary tract infections, routine disruptions, or re-triggered personal trauma first [7, 22, 27]. Pharmacological Management and Black Box Safety. - **Cholinesterase inhibitors**: **Donepezil**, **rivastigmine**, and **galantamine** offer modest, time-limited stabilization of cognitive and behavioral symptoms in mild-to-moderate Alzheimer's disease, but they do not restore functioning to pre-disease baseline [4, 27-29]. - **NMDA receptor antagonists**: **Memantine** modulates glutamate and provides clinical synergy when added to cholinesterase inhibitors in moderate-to-severe Alzheimer's dementia source 21. - **Antipsychotic prescribing rules**: Low-dose **brexpiprazole**, **quetiapine**, or **risperidone** should be short-term emergency options for severe agitation, combativeness, or unmanageable safety risks only [13, 16]. - **Safety alert**: All typical and atypical antipsychotics double the risk of mortality in elderly patients with NCD-related psychosis, caused predominantly by sudden cardiac arrest, heart failure, or aspiration pneumonia [14, 15]. Fitzgerald Practice Questions. Question 3. Mrs. Little is a 78-year-old woman with recently diagnosed Alzheimer's disease who presents for an office visit with her 55-year-old daughter source 9. According to her daughter, Mrs. Little struggles with word finding, has difficulty following directions, sometimes seems to not care about what is going on around her, and experiences angry verbal outbursts triggered by minor problems source 30. Her daughter states that this behavior is unusual, as her mother is normally very patient source 31. Mrs. Little resides with her daughter and family, who wish to care for her at home as long as it is safe [31, 32]. When evaluating Mrs. Little's healthcare needs, which of the following are pertinent options? Select all that apply [7, 32]. A) A home safety evaluation should be conducted and appropriate modifications carried out source 32. B) If Mrs. Little has a sudden change in mental status, healthcare providers should be contacted as soon as possible source 32. C) Behavioral difficulties often arise in individuals with Alzheimer's disease if their usual routine is disrupted source 7. D) The use of a cholinesterase inhibitor will likely improve her mental status to a point that is nearly equivalent to her pre-disease baseline source 7. E) Mrs. Little should be evaluated for a concomitant mood disorder source 33. F) The most common adverse effects from cholinesterase inhibitor use include nausea and diarrhea source 33. G) A second-generation antipsychotic should be started to help avoid the angry outbursts source 33. Pause. Answer: A, B, C, E, and F [28, 33]. - **Why choices A, B, C, E, and F are correct**: Home safety modifications prevent injury and wandering [6, 32]. Sudden mental status changes signal acute delirium requiring prompt medical evaluation [32, 34]. Routine disruptions frequently trigger catastrophic emotional reactions in Alzheimer's patients source 7. Depressive mood disorders co-occur in up to 50% of NCD cases and exacerbate behavioral distress [33, 35]. Gastrointestinal hypermotility causing nausea and diarrhea is the primary side-effect profile of cholinesterase inhibitors source 33. - **Why choice D fails**: Cholinesterase inhibitors provide only modest, temporary symptom stabilization and never restore mental status to a pre-disease baseline [27, 28]. - **Why choice G fails**: Second-generation antipsychotics are contraindicated for routine behavioral outbursts due to the FDA boxed warning for increased mortality and should never be used as first-line behavior management [13, 14, 27]. Question 5. A 74-year-old male is brought into the clinic for evaluation after recent erratic behavior, including confusion that can last a few hours at a time up to three times per day over the past month source 36. The caregiver reports that he recently started to take a new medication source 36. Which of the following medications is least likely to cause these episodes? source 11 A) Diphenhydramine source 11 B) Sertraline source 11 C) Haloperidol source 11 D) Diazepam source 11 Pause. Answer: B [11, 12]. - **Why choice B is correct**: Sertraline is an SSRI antidepressant that is safe in older adults and least likely to precipitate acute confusion or fluctuating delirium [11, 12, 22]. - **Why choice A fails**: Diphenhydramine possesses potent anticholinergic activity, which directly induces central nervous system toxicity, confusion, and delirium in older adults [11, 37, 38]. - **Why choice C fails**: Haloperidol is a high-potency first-generation antipsychotic that can cause acute extrapyramidal symptoms, cognitive blunting, and fluctuating confusion [11, 13, 38]. - **Why choice D fails**: Diazepam is a long-acting benzodiazepine that accumulates in older adults, causing sedation, ataxia, memory impairment, and paradoxical delirium [11, 12, 38]. Question 7. In what stage of major neurocognitive disorder do cholinesterase inhibitors demonstrate the most benefit? [29, 39] A) Mild neurocognitive disorder source 29 B) Early Alzheimer's disease source 29 C) Mild to moderate Alzheimer's disease source 29 D) Severe Alzheimer's disease source 29 Pause. Answer: C source 29. - **Why choice C is correct**: Clinical evidence demonstrates that cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine provide their primary therapeutic window and maximum symptom delay during mild to moderate Alzheimer's disease [4, 29]. - **Why choice A fails**: Cholinesterase inhibitors are not routinely recommended or approved for mild neurocognitive disorder [29, 40, 41]. - **Why choices B and D fail**: Early Alzheimer's is an informal label rather than a diagnostic staging standard source 29, whereas severe Alzheimer's disease requires NMDA receptor antagonists like memantine, often as combined therapy, rather than cholinesterase inhibitor monotherapy [21, 29]. Question 8. Your patient with major neurocognitive disorder develops severe bradycardia, gait disturbances, rigidity, and tremor after taking a low-dose second-generation antipsychotic for severe hallucinations source 19. Which neurocognitive disorder type do you suspect? source 19 A) Alzheimer's disease source 19 B) Vascular disease source 19 C) Frontotemporal disease source 19 D) Lewy body disease [19, 20] Pause. Answer: D source 20. - **Why choice D is correct**: Patients with Lewy body disease display severe neuroleptic sensitivity; exposure to even low-dose antipsychotics can precipitate catastrophic parkinsonism, profound rigidity, severe bradycardia, and neuroleptic malignant syndrome [17-20, 42]. - **Why choice A fails**: Alzheimer's disease presents primarily with memory loss and cortical deficits without severe, immediate neuroleptic sensitivity [19, 42, 43]. - **Why choice B fails**: Vascular neurocognitive disorder features step-wise cognitive decline from cerebrovascular infarcts rather than extreme adverse reactions to dopamine blockade [19, 40, 43]. - **Why choice C fails**: Frontotemporal neurocognitive disorder is characterized by early personality changes and language breakdown without acute neuroleptic-induced parkinsonism [19, 44]. Next. New section. Table: Pharmacology Treatment Considerations. Topic. SSRI and TCA Considerations. Bottom Line Summary. * **Start low and go slow, but titrate to therapeutic goals** to avoid the common clinical mistake of under-treating depression in older adults. * **SSRI hyponatremia risk**: Selective serotonin reuptake inhibitors carry a significant risk of hyponatremia in older adults, particularly when combined with thiazide diuretics like hydrochlorothiazide or ACE inhibitors like lisinopril [1-3]. * **Hyponatremia outcomes**: Low sodium levels set older adults up for acute delirium, gait instability, and falls [1, 3]. * **TCA avoidance**: Tricyclic antidepressants like amitriptyline must be avoided in older adults due to severe anticholinergic adverse effects, orthostatic hypotension, cardiac dysrhythmias, and fall risk [2-5]. * **Anticholinergic toxicity spectrum**: Anticholinergic toxicity presents peripherally as dry mouth, constipation, and blurry vision, and centrally as agitation, anxiety, confusion, visual hallucinations, delirium, psychosis, seizures, and coma [4, 6]. * **Pre-prescribing organ assessment**: Baseline renal and hepatic function tests must be completed prior to initiating psychotropic pharmacotherapy due to age-related organ clearance changes [7, 8]. * **ECT safety in elders**: Electroconvulsive therapy (ECT) is safe and highly effective for individuals over 65 years of age with severe or treatment-resistant depression [7, 8]. * **Polypharmacy risk**: Polypharmacy is a major geriatric syndrome that increases drug-drug interactions, requiring routine medication reconciliation including over-the-counter products [1, 7]. Detailed Clinical Teaching: SSRI and TCA Considerations. First-line pharmacotherapy for late-life depression requires starting SSRIs at reduced doses and slowly titrating upward to full therapeutic efficacy [8, 9]. While SSRIs are generally preferred over older drug classes, the primary Safety alert for SSRIs in geriatric practice is drug-induced hyponatremia caused by SIADH [1, 3]. Older adults frequently take co-prescribed cardiovascular medications like lisinopril or hydrochlorothiazide [2, 3]. Combining an SSRI with a diuretic synergistically increases the risk of hyponatremia, leading to subtle cognitive changes, gait disturbances, falls, and acute delirium [1, 3]. Board trap: Test questions often present an older adult taking an SSRI and a diuretic who develops sudden unsteadiness or confusion source 3. Candidates frequently select a primary neurocognitive workup, whereas the board is testing SSRI-induced hyponatremia and fluid/electrolyte imbalance [1, 3]. Tricyclic antidepressants such as amitriptyline are flagged by the Beers criteria and START/STOPP screening tools as drugs to avoid in older adults [2, 3, 5]. TCAs cause significant alpha-1 adrenergic blockade leading to orthostatic hypotension and severe fall risk [3-5]. Furthermore, TCAs possess strong anticholinergic properties that produce both peripheral and central toxicity [2, 6, 10]. Peripheral anticholinergic effects include dry mouth, severe constipation, urinary retention, and blurry vision source 6. Central anticholinergic toxicity induces agitation, anxiety, memory impairment, confusion, visual hallucinations, delirium, psychosis, seizures, and coma source 6. Safety alert: Renal and hepatic function must be evaluated prior to initiating any psychotropic agent in older adults because age-related organ decline slows drug metabolism and excretion [7, 8]. Additionally, electroconvulsive therapy (ECT) is safe and highly effective for elders over age 65 and should not be avoided simply due to advanced age [7, 8]. Fitzgerald Sample Board Questions for This Leaf. Question 2. According to the recommendations found in the Beers criteria and START/STOPP screening tools, the use of certain medications should be avoided or used with caution in older adults source 5. Match the medication with the clinical rationale: Which medication carries an increased risk for hyponatremia, especially when used with a diuretic? [3, 11] * A. Zolpidem * B. Amitriptyline * C. Sertraline * D. Diazepam Pause. Answer: C source 11. Why it is correct: Sertraline is an SSRI associated with an increased risk of hyponatremia and SIADH in older adults, especially when co-administered with diuretics like hydrochlorothiazide [1, 3, 11]. Why the other choices are wrong: * A: Zolpidem is a non-benzodiazepine hypnotic associated primarily with increased fall and fracture risk in older adults source 3. * B: Amitriptyline is a TCA that carries a significant risk of orthostatic hypotension, anticholinergic toxicity, and sedation [2, 3, 5]. * D: Diazepam is a long-acting benzodiazepine that increases sedation, motor impairment, and delirium risk in older adults [12, 13]. Question 5. A 74-year-old male is brought into the clinic for evaluation after recent erratic behavior, including confusion that can last a few hours at a time up to three times per day over the past month source 14. The caregiver reports that he recently started to take a new medication source 14. Which of the following medications is least likely to cause these episodes? source 12 * A. Diphenhydramine * B. Sertraline * C. Haloperidol * D. Diazepam Pause. Answer: B source 12. Why it is correct: Sertraline is an SSRI without strong anticholinergic properties and is least likely among the options to precipitate an acute, fluctuating delirium-like presentation in an older adult source 12. Why the other choices are wrong: * A: Diphenhydramine is a first-generation antihistamine with potent anticholinergic toxicity that frequently precipitates acute delirium and confusion in older adults [12, 13]. * C: Haloperidol is a high-potency first-generation antipsychotic that can cause extrapyramidal symptoms, cognitive slowing, and paradoxical confusion source 12. * D: Diazepam is a long-acting benzodiazepine that accumulates in older adults, triggering sedation, memory impairment, ataxia, and delirium [12, 13]. Question 11. When considering therapy for a 71-year-old man with mild to moderate depression, the PMHNP considers all of the following EXCEPT: [15, 16] * A. Medication should be started at low dose and then escalated as needed [8, 16]. * B. ECT should be avoided in those over age 65 years [8, 16]. * C. Renal and hepatic function should be assessed before initiating pharmacotherapy [8, 16]. * D. Medications with less anticholinergic effect should be preferred [10, 16]. Pause. Answer: B source 8. Why it is correct: Electroconvulsive therapy (ECT) is safe and effective for older adults over age 65 [7, 8]. Stating that ECT should be avoided in elders is false, making option B the correct EXCEPT choice [7, 8]. Why the other choices are wrong: * A: Starting low and escalating slowly while targeting therapeutic goals is a standard geriatric prescribing principle [8, 9]. * C: Assessing baseline renal and hepatic clearance before starting psychotropics prevents drug accumulation and toxicity [7, 8]. * D: Selecting medications with minimal anticholinergic activity avoids delirium, dry mouth, constipation, urinary retention, and falls [2, 6, 10]. 💡 **Next Study Step:** Review **Neurocognitive Disorders (Table 14-2 and 14-8)** to master the differential diagnosis between Alzheimer's, Vascular, and Lewy Body dementias, focusing on SGA black box warnings and cholinesterase inhibitor prescribing rules. Next. Topic. Anticholinergic Toxicity Symptoms. Bottom Line Summary. * **Rule 1**: Older adults require starting psychotropic medications at 25% to 50% of standard adult starting doses, titrating slowly while avoiding under-treatment of clinical illness. * **Rule 2**: Peripheral anticholinergic side effects present as the classic triad of dry mouth, constipation, and blurry vision. * **Rule 3**: Central anticholinergic toxicity produces severe neuropsychiatric disruption, including agitation, anxiety, confusion, visual hallucinations, delirium, psychosis, seizures, and coma. * **Rule 4**: Tricyclic antidepressants like amitriptyline and first-generation antihistamines like diphenhydramine carry severe anticholinergic and alpha-1 blockade risks, significantly increasing fall risk, orthostatic hypotension, and memory impairment. * **Rule 5**: Electroconvulsive therapy (ECT) remains a safe and highly effective modality for severe or treatment-resistant depression in adults over age 65 years. * **Rule 6**: Selective serotonin reuptake inhibitors (SSRIs) like sertraline are preferred over TCAs due to low anticholinergic activity, but require monitoring for hyponatremia, especially when combined with thiazide diuretics or ACE inhibitors. Main Testable Concepts: Anticholinergic Toxicity and Prescribing in Aging. Pharmacological Considerations in Geriatric Prescribing. Pharmacokinetic and pharmacodynamic changes in aging alter drug distribution, metabolism, and clearance [1, 2]. Decreased glomerular filtration rate and reduced hepatic blood flow lead to drug accumulation and prolonged elimination half-lives source 2. * **First-Line**: The foundational prescribing rule in older adults is to start low and go slow, but titrate to therapeutic targets to avoid under-treating psychiatric conditions [1, 2]. Baseline renal panel, hepatic enzymes, and electrolyte panels must be drawn prior to initiating psychotropics source 2. * **Safety Alert**: Polypharmacy is a major geriatric syndrome source 2. Combining multiple central nervous system active medications increases the risk of falls, delirium, and drug interactions source 2. Over-the-counter sleep aids and cold remedies frequently contain strong anticholinergic compounds that patients omit during routine medication history taking [2, 3]. Anticholinergic Side Effects vs. Central Toxicity. Anticholinergic agents block muscarinic acetylcholine receptors throughout the central and peripheral nervous systems [4, 5]. * **Peripheral Anticholinergic Triad**: Blockade of peripheral muscarinic receptors produces decreased salivation causing dry mouth, reduced intestinal motility causing severe constipation or paralytic ileus, and ciliary muscle relaxation causing blurry vision and narrow-angle glaucoma exacerbation [4, 5]. Additional peripheral signs include urinary retention and anhidrosis [4, 5]. * **Central Anticholinergic Toxicity**: Central muscarinic receptor blockade in the brain severely impairs memory, attention, and executive function [5-7]. Toxic progression manifests as agitation, severe anxiety, confusion, frank visual or auditory hallucinations, acute delirium, psychosis, seizures, and coma [5, 7]. * **Board Trap**: Test writers often present an older adult taking diphenhydramine or amitriptyline who develops new-onset confusion and visual hallucinations [4, 5, 7-10]. Students frequently fall into the trap of misdiagnosing this acute state as worsening dementia or late-onset schizophrenia, rather than recognizing drug-induced anticholinergic toxicity and delirium [5, 7, 10, 11]. High-Risk Medication Classes and Beers Criteria. The Beers Criteria and START/STOPP guidelines flag high-risk drug classes that should be avoided in older adults due to unacceptable adverse effect profiles source 8. * **Toxicity Drivers**: Amitriptyline, imipramine, and doxepin possess potent anticholinergic, antihistaminic, and alpha-1 adrenergic blocking properties [4, 8]. They cause severe orthostatic hypotension, cardiac conduction delays, QTc prolongation, and cognitive decline [4, 12]. * **First-Generation Antihistamines**: Diphenhydramine and hydroxyzine readily cross the blood-brain barrier, causing profound central anticholinergic toxicity, sedation, motor incoordination, and fall-related fractures [7-10]. * **Selective Serotonin Reuptake Inhibitors**: SSRIs like sertraline and escitalopram are preferred over TCAs because they lack significant anticholinergic activity [4, 6, 11, 13]. However, SSRIs carry a risk of hyponatremia due to SIADH, especially when combined with lisinopril or hydrochlorothiazide [3, 4, 11]. * **Electroconvulsive Therapy Safety**: ECT is a safe, highly effective modality for severe, delusional, or treatment-resistant depression in older adults [2, 13, 14]. **Board Trap**: Expect questions claiming ECT is contraindicated in adults over age 65 years. ECT is safe, well-tolerated, and highly effective in geriatric populations [2, 13, 14]. Compare and Distinguish: Peripheral vs. Central Anticholinergic Effects. Peripheral Anticholinergic Effects vs. Central Anticholinergic Toxicity. * **Peripheral Effects**: * **Think**: Classic physical mucosal and autonomic blockade triad [4, 5]. * **Defining Features**: Dry mouth, severe constipation, blurry vision, urinary hesitation or retention, and reduced sweating [4, 5]. * **Clinical Urgency**: Causes discomfort and physical complications like impaction or urinary tract infections, but is non-fatal if managed early [4, 5]. * **Central Toxicity**: * **Think**: Acute brain failure and neurocognitive emergency [5, 7, 11]. * **Defining Features**: Rapid-onset confusion, visual hallucinations, picking at air, fluctuating level of consciousness, delirium, seizures, and coma [5, 7, 11]. * **Clinical Urgency**: Immediate life-threatening medical emergency requiring prompt drug discontinuation, supportive care, and safety stabilization [5, 7, 11]. Amitriptyline vs. Sertraline in Older Adults. * **Amitriptyline**: * **Think**: High-risk tricyclic antidepressant to avoid in geriatrics [4, 8, 9]. * **Defining Features**: Heavy anticholinergic burden, high orthostatic hypotension risk, QTc prolongation, and high delirium potential [4, 8, 9]. * **Board Reality**: Incorrect choice for elderly depression due to Beers Criteria red flags [8, 9]. * **Sertraline**: * **Think**: Preferred first-line geriatric antidepressant [4, 9-11]. * **Defining Features**: Negligible anticholinergic activity, minimal cardiac effect, and favorable safety profile [4, 10, 11]. * **Board Reality**: Correct first-line choice, requiring routine monitoring of serum sodium levels for hyponatremia [3, 4, 11]. Board-Style Sample Test Questions. Question 1. A 74-year-old male is brought to the outpatient clinic by his daughter for evaluation of recent erratic behavior source 15. The daughter reports that over the past month, her father has experienced episodes of severe confusion and disorientation that last a few hours at a time, occurring up to three times per day source 15. She notes that he recently started taking a new over-the-counter medication for sleep and seasonal allergies source 15. Which of the following medications is least likely to cause these confusional episodes source 10? A. Diphenhydramine B. Sertraline C. Haloperidol D. Diazepam Pause. Answer: B. Why It Is Correct: Sertraline is a selective serotonin reuptake inhibitor with minimal anticholinergic and sedative activity [4, 10, 11]. It is the least likely agent among the choices to precipitate acute delirium or fluctuating cognitive confusion in an older adult source 10. Why the Other Choices Are Wrong: * **A**: Diphenhydramine is a potent first-generation antihistamine with strong anticholinergic properties that directly cause acute delirium, memory disruption, and confusion in older adults [7, 10]. * **B**: Sertraline is the correct answer to the least likely stem because it carries negligible anticholinergic burden source 10. * **C**: Haloperidol is a first-generation antipsychotic with anticholinergic and extrapyramidal effects that can induce or exacerbate delirium and cognitive disruption source 10. * **D**: Diazepam is a long-acting benzodiazepine that causes significant sedation, cognitive impairment, ataxia, and fluctuating delirium in geriatric patients source 10. Question 2. When initiating antidepressant therapy for a 71-year-old man presenting with mild to moderate major depressive disorder, the Psychiatric-Mental Health Nurse Practitioner considers essential geriatric prescribing principles [13, 16]. Which of the following statements is incorrect regarding his care [13, 16]? A. Medication should be started at a low initial dose and escalated slowly as clinically indicated [14, 16]. B. Electroconvulsive therapy should be strictly avoided in patients over 65 years of age due to high mortality [13, 14]. C. Baseline renal and hepatic laboratory function must be assessed prior to initiating psychotropic pharmacotherapy [13, 14]. D. Antidepressant medications with minimal anticholinergic adverse effects should be preferred [6, 13]. Pause. Answer: B. Why It Is Correct: Option B is a false statement, making it the correct choice for this incorrect statement question [13, 14]. Electroconvulsive therapy is proven to be safe and highly effective for severe or treatment-resistant depression in older adults over age 65 years, and advancing age is not a contraindication [2, 13, 14]. Why the Other Choices Are Wrong: * **A**: Starting at low doses and titrating gradually is a mandatory geriatric prescribing rule to prevent drug accumulation and toxicity [1, 14, 16]. * **B**: Electroconvulsive therapy is safe in older adults, so stating it should be strictly avoided is false and key to the correct answer [2, 13, 14]. * **C**: Assessing baseline renal and hepatic clearance function is essential before prescribing due to age-related organ decline [2, 13, 14]. * **D**: Selecting agents with low anticholinergic activity avoids triggering dry mouth, urinary retention, cognitive decline, and delirium [4-6, 13]. Question 3. An 82-year-old female living in an assisted living facility is prescribed amitriptyline for depressive symptoms and neuropathic pain [4, 8, 9]. Two weeks after starting the medication, she develops severe dry mouth, constipation, blurry vision, and visual hallucinations of insects crawling on her bed [4, 5, 17]. Which physiological mechanism best explains her presenting symptom cluster [4, 5]? A. Central and peripheral blockade of muscarinic acetylcholine receptors B. Potent selective inhibition of presynaptic serotonin reuptake transporters C. Antagonism of postsynaptic dopamine D2 receptors in the mesolimbic pathway D. Potent stimulation of central gamma-aminobutyric acid type A receptors Pause. Answer: A. Why It Is Correct: Muscarinic receptor blockade by tricyclic antidepressants like amitriptyline causes both peripheral anticholinergic signs (dry mouth, constipation, blurry vision) and central anticholinergic toxicity (hallucinations, agitation, delirium) [4, 5, 8, 9]. Why the Other Choices Are Wrong: * **A**: Blockade of muscarinic acetylcholine receptors accounts for both peripheral anticholinergic effects and central delirium [4, 5]. * **B**: Selective serotonin reuptake inhibition causes serotonergic effects like mild nausea or hyponatremia, not the anticholinergic toxicity cluster [3, 4, 11]. * **C**: Dopamine D2 receptor blockade causes extrapyramidal symptoms or hyperprolactinemia, rather than classic anticholinergic signs [10, 18]. * **D**: Stimulation of GABA-A receptors causes sedation and anxiolysis, not dry mouth, constipation, or anticholinergic delirium [7, 10]. 💡 *Would you like to test your recall with a set of 5 board-style practice questions on distinguishing Delirium, Dementia, and Depression in older adults?* Next. End of this drive.